23 results
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
. Agreement to Arbitrate.
(a)Notwithstanding any express provision to the contrary, Executive and the Company agree that any claim, controversy or dispute
8-K
EX-10.01
ADAP
Adaptimmune Therapeutics Plc
26 Jan 22
Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer
8:05am
to Arbitrate.
(a) Notwithstanding any express provision to the contrary, Executive and the Company agree that any claim, controversy or dispute
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
16 Dec 20
Departure of Directors or Certain Officers
5:01pm
express provision to the contrary, Executive and the Company agree that any claim, controversy or dispute between Executive and the Company (including
S-3ASR
EX-1.2
hhkns3czfeprxwrd
10 Aug 20
Automatic shelf registration
5:01pm
8-K
EX-1.1
zhcmuhc 9m
2 Jun 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
4:49pm
8-K
EX-1.1
q1j73lbsq
22 Jan 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
5:30pm
8-K
EX-10.1
mo4b0s8mfm22uw4xzp40
13 Jan 20
Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership
8:42am
8-K
EX-10.1
tno6qn2aa
27 Aug 19
Entry into a Material Definitive Agreement
8:39am
8-K
EX-10.1
a3jl97
1 Aug 19
New Executive Team Announced at Adaptimmune
7:22am
8-K
EX-10.1
8p65n
27 Jun 19
Departure of Directors or Certain Officers
8:08am
10-Q/A
EX-10.13
qfbqo
6 Apr 17
Quarterly report (amended)
12:00am
10-K
EX-10.20
zhw o3urq0ny4
13 Mar 17
Annual report
12:00am
10-K
EX-10.18
baipctlm
13 Mar 17
Annual report
12:00am